GlucoTrack Stock Set to Reverse Split on Monday, August 31st (NASDAQ:GCTK)

GlucoTrack, Inc. (NASDAQ:GCTK)’s stock is scheduled to reverse split on the morning of Monday, August 31st. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 30th.

GlucoTrack Price Performance

GCTK traded down $0.03 on Thursday, hitting $0.29. 1,670,509 shares of the company’s stock were exchanged, compared to its average volume of 24,427,032. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.46 and a quick ratio of 0.46. The stock has a fifty day moving average of $0.39 and a two-hundred day moving average of $0.75. GlucoTrack has a twelve month low of $0.25 and a twelve month high of $14.14.

GlucoTrack (NASDAQ:GCTK) last posted its earnings results on Friday, August 14th. The company reported $0.76 earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

GCTK has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a report on Friday, July 17th. Wall Street Zen raised GlucoTrack from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On GlucoTrack

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in shares of GlucoTrack by 102,125.0% during the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after acquiring an additional 4,085 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack in the fourth quarter valued at about $52,000. Finally, Ikarian Capital LLC bought a new position in shares of GlucoTrack in the fourth quarter worth about $177,000. 10.92% of the stock is owned by hedge funds and other institutional investors.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.